Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tango Therapeutics granted a new employee equity awards under its 2023 Inducement Plan, effective September 1, 2026. The package includes a non-qualified stock option to purchase 146,500 shares at an exercise price of $22.35 — equal to the September 1 closing price — plus 40,000 restricted stock units. Options vest 25% on the first anniversary of the employee's start date, then 1/36th of the remainder monthly; RSUs vest in three equal annual installments, all contingent on continued employment.
Key figures
- Grant date
- 2026-09-01
- Rsu shares
- 40000
- Option shares
- 146500
- Exercise price usd
- 22.35
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.